Calyx bags 5-year data management contract with top 10 pharma firms

Author : Pankaj Singh | Published Date : 2021-10-26 

Calyx’s industry-leading RIM (Regulatory Information Management) system has reportedly been selected by the world’s top 10 pharma companies for critical submissions of clinical development data to global regulators through 2026.

The five-year contract signed by the top 10 companies with Calyx demonstrates the continued use of RIM, ensuring fulfillment of regulatory requirements worldwide.

In this context, John Blakeley, Chief Commercial Officer at Calyx, expressed that they value the faith the global pharmaceutical firms have put in them and are thrilled to continue their relationship while providing breakthrough medical treatments and vaccines to people across the globe.

Calyx’s selection can be credited to the companies’ long history with the Calyx RIM solution and the confidence that the firm will continue to support submissions across the company's broad worldwide portfolio.

Calyx RIM, developed by Calyx in-house regulatory professionals, is a tested, proven, robust technology that streamlines and improves the regulatory submission process, and is constantly updated to match worldwide health authorities' rising submission standards.

Calyx RIM publication module allows pharmaceutical businesses to build and submit comprehensive dossiers to worldwide regulatory agencies.

The company’s relationship with Microsoft, and its usage of new cloud-based technologies that keep customers ahead of developing regulatory standards, further adds to the RIM system's value. Calyx RIM on Microsoft Azure delivers system upgrades targeted to customers' needs and schedules, guaranteeing minimal downtime and continued compliance with global regulatory requirements.

Calyx, with its proficiency in clinical development and over 25 years of experience in aiding trial sponsors and clinical research institutions to solve complexities, offers timely insights and brings innovative medications to the industry through innovative eClinical and Regulatory solutions and services. The company has supported over 60,000 trials, 75+ breakthrough therapy approvals, and over 18 million patients to date.

Source Credit-


About Author

Pankaj Singh

Pankaj Singh

Endowed with a post graduate degree in management and finance, Pankaj Singh has been a part of the online content domain for quite a while. Having worked previously as a U.K. insurance underwriter for two years, he now writes articles for fractovia.org and other online portals. He can be contacted at- [email protected] | https://twitter.com/PankajSingh2605

Related News

General Motors expects positive results as supply chain strains ease

Published Date: 2021-12-03         Author: Pankaj Singh

Chief Financial Officer of General Motors Co., Paul Jacobson, reportedly stated that the carmaker expects full-year adjusted pre-tax profits to be around USD 14 billion, higher than the previous prediction of USD 11.5 billion to USD 13.5 billion. Strong consumer demand, high vehicle prices, and s... Read More

Global airlines prepping for a new wave of volatility posed by Omicron

Published Date: 2021-12-02         Author: Pankaj Singh

International airlines are reportedly preparing to combat the emerging threat posed by the new variant of coronavirus, Omicron, which might compel them to modify destinations and schedules on short notice and gravitate more towards domestic markets. Although many passengers have already booked tr... Read More

Celltrion to supply COVID-19 antibody therapy to 9 European countries

Published Date: 2021-12-01         Author: Pankaj Singh

South Korean biopharma company Celltrion has reportedly signed agreements with nine European countries to provide Regkirona (regdanvimab), a monoclonal antibody therapy for COVID-19. The European Commission in November granted the drug marketing authorization for adults infected with the virus wh... Read More

© 2021 Fractovia. All Rights Reserved